Clarke Shoa L, Huang Rose D L, Hilliard Austin T, Levin Michael G, Sharma Disha, Thomson Blake, Lynch Julie, Tsao Philip S, Gaziano J Michael, Assimes Themistocles L
VA Palo Alto Healthcare System, 3801 Miranda Avenue, Palo Alto, CA, 94304, USA.
Department of Medicine, Stanford Prevention Research Center, Stanford University School of Medicine, 300 Pasteur Drive, Palo Alto, CA, 94304, USA.
Eur J Prev Cardiol. 2025 Jan 27;32(2):116-127. doi: 10.1093/eurjpc/zwae271.
AIMS: Elevated lipoprotein(a) [Lp(a)] is a causal risk factor for atherosclerotic cardiovascular disease, but the mechanisms of risk are debated. Studies have found inconsistent associations between Lp(a) and measurements of atherosclerosis. We aimed to assess the relationship between Lp(a), low-density lipoprotein cholesterol (LDL-C), and coronary artery plaque severity. METHODS AND RESULTS: The study population consisted of participants of the Million Veteran Program who have undergone an invasive angiogram. The primary exposure was genetically predicted Lp(a) estimated by a polygenic score. Genetically predicted LDL-C was also assessed for comparison. The primary outcome was coronary artery plaque severity categorized as normal, non-obstructive disease, one-vessel disease, two-vessel disease, and three-vessel or left main disease. Among 18 927 adults of genetically inferred European ancestry and 4039 adults of genetically inferred African ancestry, we observed consistent associations between genetically predicted Lp(a) and obstructive coronary plaque, with effect sizes trending upward for increasingly severe categories of disease. Associations were independent of risk factors, clinically measured LDL-C and genetically predicted LDL-C. However, we did not find strong or consistent evidence for an association between genetically predicted Lp(a) and risk for non-obstructive plaque. CONCLUSION: Genetically predicted Lp(a) is positively associated with coronary plaque severity independent of LDL-C, consistent with Lp(a) promoting atherogenesis. However, the effects of Lp(a) may be greater for progression of plaque to obstructive disease than for the initial development of non-obstructive plaque. A limitation of this study is that Lp(a) was estimated using genetic markers and could not be directly assayed nor could apo(a) isoform size.
目的:脂蛋白(a)[Lp(a)]升高是动脉粥样硬化性心血管疾病的一个因果风险因素,但风险机制存在争议。研究发现Lp(a)与动脉粥样硬化测量值之间的关联并不一致。我们旨在评估Lp(a)、低密度脂蛋白胆固醇(LDL-C)与冠状动脉斑块严重程度之间的关系。 方法和结果:研究人群包括参加百万退伍军人计划且接受过侵入性血管造影的参与者。主要暴露因素是通过多基因评分估计的遗传预测Lp(a)。还评估了遗传预测的LDL-C以作比较。主要结局是冠状动脉斑块严重程度,分为正常、非阻塞性疾病、单支血管疾病、双支血管疾病和三支血管或左主干疾病。在18927名遗传推断为欧洲血统的成年人和4039名遗传推断为非洲血统的成年人中,我们观察到遗传预测的Lp(a)与阻塞性冠状动脉斑块之间存在一致的关联,疾病严重程度越高,效应量呈上升趋势。这些关联独立于风险因素、临床测量的LDL-C和遗传预测的LDL-C。然而,我们没有发现遗传预测的Lp(a)与非阻塞性斑块风险之间存在强关联或一致证据。 结论:遗传预测的Lp(a)与冠状动脉斑块严重程度呈正相关,独立于LDL-C,这与Lp(a)促进动脉粥样硬化形成一致。然而,Lp(a)对斑块进展为阻塞性疾病的影响可能比对非阻塞性斑块的初始形成影响更大。本研究的一个局限性是Lp(a)是使用遗传标记估计的,无法直接检测,也无法检测载脂蛋白(a)异构体大小。
Cochrane Database Syst Rev. 2025-5-7
Cochrane Database Syst Rev. 2025-1-29
Cochrane Database Syst Rev. 2025-6-16
Cochrane Database Syst Rev. 2024-1-8
Cochrane Database Syst Rev. 2025-6-19
Cochrane Database Syst Rev. 2025-6-13
Autism Adulthood. 2025-5-28
Eur J Prev Cardiol. 2024-11-11
Eur J Prev Cardiol. 2024-5-11
J Am Coll Cardiol. 2024-1-23
J Am Coll Cardiol. 2024-1-23
J Am Heart Assoc. 2023-9-19
Curr Opin Lipidol. 2023-4-1